Management of Relapsed Diffuse Large B-cell Lymphoma
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference89 articles.
1. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001;Morton;Blood,2006
2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma;Coiffier;N Engl J Med,2002
3. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006
4. Long term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Group D’Etude des Lymphomes de L’Adulte;Feugier;J Clin Oncol,2005
5. Phase II Study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014;Persky;J Clin Oncol,2008
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG);Annals of Hematology;2023-05-18
2. PD‐L1 expression predicts efficacy in the phase II SPiReL trial with MVP‐S, pembrolizumab, and low‐dose CPA in R/R DLBCL;European Journal of Haematology;2023-05-08
3. EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16;Leukemia & Lymphoma;2022-10-14
4. The genetic deletion and protein expression of PRDM1 and its clinical implications in diffuse large B cell lymphoma: A retrospective cohort study in China;Pathology - Research and Practice;2022-05
5. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma;Blood Advances;2022-04-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3